Clarenta buys France's Leads To Development to bridge preclinical and clinical work
What's the deal? ClarentaDealroom has a profile for this one. Try Dealroom → has acquired France's Leads To DevelopmentDealroom has a profile for this one. Try Dealroom → (L2D) through a majority investment, adding early-stage drug development expertise to its clinical consulting business. The deal, announced September 30, 2026, had undisclosed terms.
What each does: Clarenta, formerly Comac Medical GroupDealroom has a profile for this one. Try Dealroom →, is a European clinical development partner running studies through its Phase I Unit and delivering trials across Europe. Paris-based L2D, founded over 15 years ago, provides non-clinical development, manufacturing, and regulatory strategy consulting for biotech and pharmaceutical firms.
Why now? L2D joins shortly after Clarenta launched a new brand identity, part of its strategy to build an integrated early development partner. The addition strengthens the link between early scientific strategy and first-in-human clinical research.
What's the endgame? Clarenta wants to support sponsors from preclinical strategy through first-in-human trials and beyond. L2D fills the earliest stage of that journey, adding non-clinical, manufacturing, and regulatory expertise.
"Our focus is on helping clients navigate complexity from the earliest stages of development," said Dr. Chris Smyth, chief executive officer of Clarenta. He said L2D brings expertise that helps sponsors "connect the decisions made before the clinic with the realities of early clinical development."
What changes for clients? L2D will keep operating from its Paris headquarters as a specialist team, serving existing and new clients while drawing on Clarenta's broader capabilities. Managing director and co-founder Jonathan Kearsey said working with Clarenta lets L2D "connect those preclinical decisions with clinical strategies."
The signal: The deal reflects consolidation among drug development service providers seeking to offer sponsors a single partner across the preclinical-to-clinical divide. Christopher Backes, co-founder of majority investor EdgeCap PartnersDealroom has a profile for this one. Try Dealroom →, called L2D "a strong strategic fit," adding expertise "where better decisions can create meaningful value for clients."
Read more: prnewswire.com
Image credit: foteih
